首页> 外国专利> Antihuman CCR7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier

Antihuman CCR7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier

机译:抗人CCR7抗体,杂交瘤,核酸,载体,细胞,药物组合物和固定有抗体的载体

摘要

The purpose of the present invention is to provide a novel antihuman CCR7 antibody which is useful as a therapeutic agent for tissue fibrosis or cancer, a medicinal composition which comprises the antihuman CCR7 antibody, and so on. Provided is an antihuman CCR7 antibody binding specifically to the extracellular domain of human CCR7, said antihuman CCR7 antibody having a heavy chain CDR3 which comprises an amino acid sequence represented by SEQ ID NO: 7, 17, 27, 37, 47, 57, 67 or 77. Also provided is an antihuman CCR7 antibody which has heavy chain CDRs 1-3 and light chain CDRs 1-3, said heavy chain CDRs 1-3 and light chain CDRs 1-3 respectively comprising amino acid sequences represented by SEQ ID NOS:5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70 or 75-80. Preferably, such an antihuman CCR7 antibody has an activity of blocking CCR7-dependent intracellular signal transduction mechanism that is induced by stimulation with CCR7 ligands. The antihuman CCR7 antibodies according to the present invention are usable as the active ingredient of a therapeutic agent for tissue fibrosis or cancer.
机译:本发明的目的是提供可用作组织纤维化或癌症的治疗剂的新型抗人CCR7抗体,包含该抗人CCR7抗体的药物组合物等。提供了特异性结合人CCR7的胞外域的抗人CCR7抗体,所述抗人CCR7抗体具有重链CDR3,其包含由SEQ ID NO:7、17、27、37、47、57、67表示的氨基酸序列。或77.还提供了具有重链CDR 1-3和轻链CDR 1-3的抗人CCR7抗体,所述重链CDR 1-3和轻链CDR 1-3分别包含SEQ ID NOS所示的氨基酸序列。 :5-10、15-20、25-30、35-40、45-50、55-60、65-70或75-80。优选地,这样的抗人CCR7抗体具有阻断由CCR7配体刺激而诱导的依赖CCR7的细胞内信号转导机制的活性。根据本发明的抗人CCR7抗体可用作组织纤维化或癌症的治疗剂的活性成分。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号